Biotech Values

[poorgradstudent]

Yes.

For that ASSIST-1 trial, patients need to have failed one of Doxil or Hycamtin in the second line. They are then randomized to receive either Telcyta or one of Doxil / Hycamtin, depending on which of that pair they previously failed. So for example, if a woman failed Doxil in the second line, she would be eligible to receive either Telcyta or Hycamtin.

They also have another phase III in 2nd line ovarian cancer called ASSIST-3. Patients failing first line platinum are randomized to Telcyta + carbo or Doxil. It's basically a resensitization trial. However, this one is still enrolling so it is difficult to have a good estimate for completion. The company has stated that all three ASSIST trials are likely to come to completion under a similar time frame.